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Within the area of alopecia areata research, there is an obvious need for well-
designed clinical trials of therapeutic agents. The National Alopecia Areata
Foundation (NAAF) has created an initiative for the development of a unified
protocol with guidelines for clinical studies. The NAAF universal protocol
represents a joint effort of clinicians and investigators with experience in treating
alopecia areata. This protocol will serve as a tremendous resource to facilitate
future clinical studies.
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The advances in genetic and immunologic
studies of alopecia areata have set forth
new standards for the development of
effective treatments. There is a strong need
for well-controlled clinical trials in alope-
cia areata, as current treatments fall short
in efficacy, standardization, and validity.
The National Alopecia Areata Foun-
dation (NAAF) has supported an initia-
tive to facilitate better clinical studies of
therapeutic agents. The NAAF universal
protocol represents a joint effort of
clinicians and investigators with experi-
ence in treating alopecia areata. It has
been developed as a comprehensive
yet adaptable resource to be used for
clinical trials. The protocol outline is
based on anticipated 12 and 24 weeks
therapeutic end points, with effi-
cacy scoring utilizing the validated
Severity of Alopecia Tool criteria by
Olsen et al.
The components of the protocol include:
(1) A clinical trial protocol template, with
applicable sets of inclusion and exclu-
sion criteria, study parameters, and
suggested statistical formats, accom-
modating medications or devices.
(2) Practical forms, charts, and work-
sheets to facilitate study visits.
(3) Instructions to assist with stan-
dardized photography, Severity of
Alopecia Tool scoring, and patient
self-assessment diaries.
The goal of the uniform protocol is to
simplify and promote future clinical trials
for alopecia areata treatments. The format
of the uniform protocol will continue to be
refined as a reflection of ongoing studies.
Future expansions plan to incorporate alo-
pecia areata quality of life measurements.
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